Table 4.
ACQ-6 scores by time point (full analysis set)
| Time point | Benralizumab 30 mg Q4W (N=51)
|
Placebo (N=52)
|
||||
|---|---|---|---|---|---|---|
| n | Score | Change from baseline | n | Score | Change from baseline | |
| Baseline, mean (SD) | 51 | 1.95 (0.88) | 52 | 1.76 (0.95) | ||
| Week 4, mean (SD) | 51 | 1.47 (0.98) | −0.48 (0.98) | 50 | 1.44 (0.88) | −0.30 (0.74) |
| Week 8, mean (SD) | 50 | 1.47 (0.94) | −0.47 (0.89) | 50 | 1.34 (0.78) | −0.39 (0.87) |
| Week 12, mean (SD) | 50 | 1.44 (1.06) | −0.50 (1.11) | 49 | 1.29 (0.83) | −0.42 (0.93) |
Abbreviations: ACQ-6, Asthma Control Questionnaire 6; N, number of patients within each treatment group; n, number of patients in analysis; Q4W, every 4 weeks; SD, standard deviation.